Modeling the timing of antilatency drug administration during HIV treatment

Journal of Virology

Volumn 88, Issue 24, 2014, Pages 14050-14056

  Petravic, Janka ^a   Martyushev, Alexey ^a   Reece, Jeanette C ^b   Kent, Stephen J ^b   Davenport, Miles P ^b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILATENCY DRUG; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; UNCLASSIFIED DRUG; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ARTICLE; CD4+ T LYMPHOCYTE; CELL DEATH; CELL SURVIVAL; CONCENTRATION RESPONSE; CROSS-SECTIONAL STUDY; DRUG EFFICACY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LATENT VIRUS INFECTION; MATHEMATICAL MODEL; NONHUMAN; T LYMPHOCYTE ACTIVATION; TIME TO TREATMENT; TURNOVER TIME; VIRUS CARRIER; VIRUS LATENCY; VIRUS LOAD; DRUG EFFECTS; HIV INFECTIONS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; PHYSIOLOGY; THEORETICAL MODEL; TIME; VIROLOGY; VIRUS ACTIVATION;

ANTI-HIV AGENTS; HIV; HIV INFECTIONS; HUMANS; MODELS, THEORETICAL; TIME FACTORS; VIRUS ACTIVATION; VIRUS LATENCY;

EID: 84911468121     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01701-14     Document Type: Article

References (39)

1. Chun TW, Fauci AS. 1999. Latent reservoirs of HIV: obstacles to the eradication of virus. Proc. Natl. Acad. Sci. U. S. A. 96:10958-10961. http://dx.doi.org/10.1073/pnas.96.20.10958.
2. + T cells. Nat. Med. 9:727-728. http://dx.doi.org/10.1038/nm880.
3. Katlama C, Deeks SG, Autran B, Martinez-Picado J, van Lunzen Jan Rouzioux C, Miller C, Vella S, Schmitz JE, Ahlers J, Richman DD, Sékaly R-P. 2013. Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs. Lancet 381:2109-2117. http://dx.doi.org/10.1016/S0140-6736(13)60104-X.
4. + T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat. Med. 5:512-517. http://dx.doi.org/10.1038/8394.
5. Chun T-W, Davey RT, Jr, Engel D, Lane HC, Fauci AS. 1999. Reemergence of HIV after stopping therapy. Nature 401:874-875. http://dx.doi.org/10.1038/44755.
6. Margolis DM. 2010. Mechanisms of HIV latency: an emerging picture of complexity. Curr. HIV/AIDS Rep. 7:37-43. http://dx.doi.org/10.1007/s11904-009-0033-9.
7. + T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy. Nat. Med. 5:651-655. http://dx.doi.org/10.1038/9498.
8. Stellbrink H-J, van Lunzen Jan Westby M, O'Sullivan E, Schneider C, Adam A, Weitner L, Kuhlmann B, Hoffmann C, Fenske S, Aries PS, Degen O, Eggers C, Petersen H, Haag F, Horst HA, Dalhoff K, Möcklinghoff C, Cammack N, Tenner-Racz K, Racz P. 2002. Effects of interleukin-2 plus highly active antiretroviral therapy on HIV-1 replication and proviral DNA (COSMIC trial). AIDS 16:1479-1487. http://dx.doi.org/10.1097/00002030-200207260-00004.
9. Beans EJ, Fournogerakis D, Gauntlett C, Heumann LV, Kramer R, Marsden MD, Murray D, Chun T-W, Zack JA, Wender PA. 2013. Highly potent, synthetically accessible prostratin analogs induce latent HIV expression in vitro and ex vivo. Proc. Natl. Acad. Sci. U. S. A. 110: 11698-11703. http://dx.doi.org/10.1073/pnas.1302634110.
10. DeChristopher BA, Loy BA, Marsden MD, Schrier AJ, Zack JA, Wender PA. 2012. Designed, synthetically accessible bryostatin analogues potently induce activation of latent HIV reservoirs in vitro. Nat. Chem. 4:705-710. http://dx.doi.org/10.1038/nchem.1395.
11. Boehm D, Calvanese V, Dar RD, Xing S, Schroeder S, Martins L, Aull K, Li P-C, Planelles V, Bradner JE, Zhou M-M, Siliciano RF, Weinberger L, Verdin E, Ott M. 2013. BET bromodomain-targeting compounds reactivate HIV from latency via a Tat-independent mechanism. Cell Cycle 12:452-462. http://dx.doi.org/10.4161/cc.23309.
12. Shehu-Xhilaga M, Rhodes D, Wightman F, Liu HB, Solomon A, Saleh S, Dear AE, Cameron PU, Lewin SR. 2009. The novel histone deacetylase inhibitors metacept-1 and metacept-3 potently increase HIV-1 transcription in latently infected cells. AIDS 23:2047-2050. http://dx.doi.org/10.1097/QAD.0b013e328330342c.
13. Lehrman G, Hogue IB, Palmer S, Jennings C, Spina CA, Wiegand A, Landay AL, Coombs RW, Richman DD, Mellors JW, Coffin JM, Bosch RJ, Margolis DM. 2005. Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet 366:549-555. http://dx.doi.org/10.1016/S0140-6736(05)67098-5.
14. Archin NM, Liberty AL, Kashuba AD, Choudhary SK, Kuruc JD, Crooks AM, Parker DC, Anderson EM, Kearney MF, Strain MC, Richman DD, Hudgens MG, Bosch RJ, Coffin JM, Eron JJ, Hazuda DJ, Margolis DM. 2012. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 487:482-485. http://dx.doi.org/10.1038/nature11286.
15. Bullen CK, Laird GM, Durand CM, Siliciano JD, Siliciano RF. 2014. New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency. Nat. Med. 20:425-429. http://dx.doi.org/10.1038/nm.3489.
16. Kent SJ, Reece JC, Petravic J, Martyushev A, Kramski M, De Rose R, Cooper DA, Kelleher AD, Emery S, Cameron PU, Lewin SR, Davenport MP. 2013. The search for an HIV cure: tackling latent infection. Lancet Infect. Dis. 13:614-621. http://dx.doi.org/10.1016/S1473-3099(13)70043-4.
17. + T cells. PLoS Pathog. 8:e1002615. http://dx.doi.org/10.1371/journal.ppat.1002615.
18. Cohen Stuart JW, Hazebergh MD, Hamann D, Otto SA, Borleffs JC, Miedema F, Boucher CA, De Boer RJ. 2000. The dominant source of CD4+ and CD8+ T-cell activation in HIV infection is antigenic stimulation. J. Acquir. Immune Defic. Syndr. 25:203-211. http://dx.doi.org/10.1097/00126334-200011010-00001.
19. Doitsh G, Galloway NL, Geng X, Yang Z, Monroe KM, Zepeda O, Hunt PW, Hatano H, Sowinski S, Muñoz-Arias I, Greene WC. 2014. Cell death by pyroptosis drives CD4 T-cell depletion in HIV-1 infection. Nature 505:509-514. http://dx.doi.org/10.1038/nature12940.
20. Nowak MA, May RM. 2000. Virus dynamics: mathematical principles of immunology and virology. Oxford University Press, Oxford, United Kingdom.
21. Lloyd AL. 2001. The dependence of viral parameter estimates on the assumed viral life cycle: limitations of studies of viral load data. Proc. Biol. Sci. 268:847-854. http://dx.doi.org/10.1098/rspb.2000.1572.
22. Shan L, Deng K, Shroff NS, Durand CM, Rabi SA, Yang H-C, Zhang H, Margolick JB, Blankson JN, Siliciano RF. 2012. Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity 36:491-501. http://dx.doi.org/10.1016/j.immuni.2012.01.014.
23. Archin NM, Vaidya NK, Kuruc JD, Liberty AL, Wiegand A, Kearney MF, Cohen MS, Coffin JM, Bosch RJ, Gay CL, Eron JJ, Margolis DM, Perelson AS. 2012. Immediate antiviral therapy appears to restrict resting CD4+ cell HIV-1 infection without accelerating the decay of latent infection. Proc. Natl. Acad. Sci. U. S. A. 109:9523-9528. http://dx.doi.org/10.1073/pnas.1120248109.
24. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. 1995. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373:123-126. http://dx.doi.org/10.1038/373123a0.
25. Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P, Lifson JD, Bonhoeffer S, Nowak MA, Hahn BH. 1995. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373:117-122. http://dx.doi.org/10.1038/373117a0.
26. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. 1996. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 271:1582-1586. http://dx.doi.org/10.1126/science.271.5255.1582.
27. Ramratnam B, Bonhoeffer S, Binley J, Hurley A, Zhang L, Mittler JE, Markowitz M, Moore JP, Perelson AS, Ho DD. 1999. Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis. Lancet 354:1782-1785. http://dx.doi.org/10.1016/S0140-6736(99)02035-8.
28. Davenport MP, Zhang L, Shiver JW, Casmiro DR, Ribeiro RM, Perelson AS. 2006. Influence of peak viral load on the extent of CD4+ T-cell depletion in simian HIV infection. J. Acquir. Immune Defic. Syndr. 41: 259-265. http://dx.doi.org/10.1097/01.qai.0000199232.31340.d3.
29. Murray JM, McBride K, Boesecke C, Bailey M, Amin J, Suzuki K, Baker D, Zaunders JJ, Emery S, Cooper DA, Koelsch KK, Kelleher AD, on behalf of the PINT Study Team. 2012. Integrated HIV DNA accumulates prior to treatment while episomal HIV DNA records ongoing transmission afterwards. AIDS 26:543-550. http://dx.doi.org/10.1097/QAD.0b013e328350fb3c.
30. Klatt NR, Shudo E, Ortiz AM, Engram JC, Paiardini M, Lawson B, Miller MD, Else J, Pandrea I, Estes JD, Apetrei C, Schmitz JE, Ribeiro RM, Perelson AS, Silvestri G. 2010. CD8+ lymphocytes control viral replication in SIVmac239-infected rhesus macaques without decreasing the lifespan of productively infected cells. PLoS Pathog. 6:e1000747. http://dx.doi.org/10.1371/journal.ppat.1000747.
31. Wong JK, Strain MC, Porrata R, Reay E, Sankaran-Walters S, Ignacio CC, Russell T, Pillai SK, Looney DJ, Dandekar S. 2010. In vivo CD8+ T-cell suppression of SIV viremia is not mediated by CTL clearance of productively infected cells. PLoS Pathog. 6:e1000748. http://dx.doi.org/10.1371/journal.ppat.1000748.
32. Balamurali M, Petravic J, Loh L, Alcantara S, Kent SJ, Davenport MP. 2010. Does cytolysis by CD8+ T cells drive immune escape in HIV infection? J. Immunol. 185:5093-5101. http://dx.doi.org/10.4049/jimmunol.1002204.
33. Ellis L, Pan Y, Smyth GK, George DJ, McCormack C, Williams-Truax R, Mita M, Beck J, Burris H, Ryan G, Atadja P, Butterfoss D, Dugan M, Culver K, Johnstone RW, Prince HM. 2008. Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma. Clin. Cancer Res. 14:4500-4510. http://dx.doi.org/10.1158/1078-0432.CCR-07-4262.
34. Deeks SG, Autran B, Berkhout B, Benkirane M, Cairns S, Chomont N, Chun T-W, Churchill M, Di Mascio M, Katlama C, Lafeuillade A, Landay A, Lederman MM, Lewin SR, Maldarelli F, Margolis DM, Markowitz M, Martinez-Picado J, Mullins JI, Mellors JW, Moreno S, O'Doherty U, Palmer S, Penicaud M-C, Peterlin M, Poli G, Routy J-P, Rouzioux C, Silvestri G, Stevenson M, Telenti A, Van Lint C, Verdin E, Woolfrey A, Zaia J, Barre-Sinoussi F. 2012. Towards an HIV cure: a global scientific strategy. Nat. Rev. Immunol. 12:607-614. http://dx.doi.org/10.1038/nri3262.
35. Murray JM, Zaunders JJ, McBride KL, Xu Y, Bailey M, Suzuki K, Cooper DA, Emery S, Kelleher AD, Koelsch KK, for the PINT Study Team. 2014. HIV DNA subspecies persist in both activated and resting memory CD4+ T cells during antiretroviral therapy. J. Virol. 88:3516-3526. http://dx.doi.org/10.1128/JVI.03331-13.
36. Routy JP, Tremblay CL, Angel JB, Trottier B, Rouleau D, Baril JG, Harris M, Trottier S, Singer J, Chomont N, Sékaly RP, Boulassel MR. 2012. Valproic acid in association with highly active antiretroviral therapy for reducing systemic HIV-1 reservoirs: results from a multicentre randomized clinical study. HIV Med. 13:291-296. http://dx.doi.org/10.1111/j.1468-1293.2011.00975.x.
37. + cell infection. PLoS One 5:e9390. http://dx.doi.org/10.1371/journal.pone.0009390.
38. Rasmussen TA, Tolstrup M, Brinkmann CR, Olesen R, Erikstrup C, Solomon A, Winckelmann A, Palmer S, Dinarello C, Buzon M, Lichterfeld M, Lewin SR, Østergaard L, Søgaard OS. 2014. Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial. Lancet HIV 1:e13-e21. http://dx.doi.org/10.1016/S2352-3018(14)70014-1.
39. Kent SJ, Davenport MP. 2014. Tentative first steps to eradicate latent HIV. Lancet HIV 1:e2-e3. http://dx.doi.org/10.1016/S2352-3018(14)70015-3.